Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
86.85
-2.05 (-2.31%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Company Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.

It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.

Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corporation
Blueprint Medicines logo
Country United States
Founded 2008
IPO Date Apr 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 655
CEO Ms. Kathryn Haviland

Contact Details

Address:
45 Sidney Street
Cambridge, Massachusetts 02139
United States
Phone 617-374-7580
Website blueprintmedicines.com

Stock Details

Ticker Symbol BPMC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001597264
CUSIP Number 09627Y109
ISIN Number US09627Y1091
SIC Code 2834

Key Executives

Name Position
Kathryn Haviland President, Chief Executive Officer and Director
Alexis A. Borisy A.M. Co-Founder and Director
Michael Landsittel Chief Financial Officer
Christina Rossi Chief Operating Officer
Tracey L. McCain Esq. Executive Vice President, Chief Legal and Compliance Officer and Secretary
Dr. Fouad Namouni M.D. President of Research and Development
Ariel Hurley Senior Vice President, Finance and Principal Accounting Officer
Dr. Christopher K. Murray Ph.D. Senior Vice President of Technical Operations and Chief Technical Operations and Quality Officer
Dr. Percy H. Carter M.B.A., Ph.D. Chief Scientific Officer
Jenna Cohen Senior Director and Head of Investor Relations

Latest SEC Filings

Date Type Title
Apr 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 28, 2024 144 Filing
Mar 15, 2024 144 Filing
Mar 15, 2024 144 Filing
Mar 13, 2024 144 Filing
Mar 4, 2024 144 Filing
Feb 28, 2024 144 Filing
Feb 22, 2024 8-K Current Report
Feb 16, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 15, 2024 10-K Annual Report